BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 12878586)

  • 41. Plasmin as a complement C5 convertase.
    Leung LL; Morser J
    EBioMedicine; 2016 Mar; 5():20-1. PubMed ID: 27077104
    [No Abstract]   [Full Text] [Related]  

  • 42. Mechanism of activation of the classical pathway of complement by monoclonal IgE (DES). Restricted regulation of C4b by C4b-binding protein.
    Saint-Remy JM
    Eur J Immunol; 1984 Mar; 14(3):254-9. PubMed ID: 6608450
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A mechanism of activation of the alternative complement pathway by the classical pathway: protection of C3b from inactivation by covalent attachment to C4b.
    Meri S; Pangburn MK
    Eur J Immunol; 1990 Dec; 20(12):2555-61. PubMed ID: 2148521
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Positively charged amino acids at the interface between alpha-chain CCP1 and CCP2 of C4BP are required for regulation of the classical C3-convertase.
    Blom AM; Zadura AF; Villoutreix BO; Dahlbäck B
    Mol Immunol; 2000 Jun; 37(8):445-53. PubMed ID: 11090879
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Surface-dependent modulation by H of C5 cleavage by the cell-bound alternative pathway C5 convertase of human complement.
    Fischer E; Kazatchkine MD
    J Immunol; 1983 Jun; 130(6):2821-4. PubMed ID: 6222117
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The conversion of human complement component C5 into fragment C5b by the alternative-pathway C5 convertase.
    DiScipio RG
    Biochem J; 1981 Dec; 199(3):497-504. PubMed ID: 6918218
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of zinc on factor I cofactor activity of C4b-binding protein and factor H.
    Blom AM; Kask L; Ramesh B; Hillarp A
    Arch Biochem Biophys; 2003 Oct; 418(2):108-18. PubMed ID: 14522582
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Functional role of the noncatalytic subunit of complement C5 convertase.
    Rawal N; Pangburn MK
    J Immunol; 2000 Feb; 164(3):1379-85. PubMed ID: 10640753
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effects of iodine and thiol-blocking reagents on complement component C2 and on the assembly of the classical-pathway C3 convertase.
    Kerr MA; Parkes C
    Biochem J; 1984 Apr; 219(2):391-9. PubMed ID: 6611150
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of human complement components C4 and C3 with amines or chaotropic ions. Evidence of a functional and structural change that provides uncleaved C4 and C3 with properties of their soluble activated froms, C4b and C3b.
    von Zabern I; Nolte R; Vogt W
    Scand J Immunol; 1981; 13(5):413-31. PubMed ID: 6171865
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Control of the function of substrate-bound C4b-C3b by the complement receptor Cr1.
    Medof ME; Nussenzweig V
    J Exp Med; 1984 Jun; 159(6):1669-85. PubMed ID: 6233387
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A covalent dimer of complement C4b serves as a subunit of a novel C5 convertase that involves no C3 derivatives.
    Masaki T; Matsumoto M; Yasuda R; Levine RP; Kitamura H; Seya T
    J Immunol; 1991 Aug; 147(3):927-32. PubMed ID: 1861081
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Preferential inactivation of the C5 convertase of the alternative complement pathway by factor I and membrane cofactor protein (MCP).
    Seya T; Okada M; Matsumoto M; Hong KS; Kinoshita T; Atkinson JP
    Mol Immunol; 1991 Oct; 28(10):1137-47. PubMed ID: 1833639
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Purification and functional analysis of the polymorphic variants of the C3b/C4b receptor (CR1) and comparison with H, C4b-binding protein (C4bp), and decay accelerating factor (DAF).
    Seya T; Holers VM; Atkinson JP
    J Immunol; 1985 Oct; 135(4):2661-7. PubMed ID: 3161944
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of sodium chloride concentration on fluid-phase assembly and stability of the C3 convertase of the classical pathway of the complement system.
    Maeda S; Nagasawa S
    Biochem J; 1990 Nov; 271(3):749-54. PubMed ID: 2244876
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor.
    Rooijakkers SH; Wu J; Ruyken M; van Domselaar R; Planken KL; Tzekou A; Ricklin D; Lambris JD; Janssen BJ; van Strijp JA; Gros P
    Nat Immunol; 2009 Jul; 10(7):721-7. PubMed ID: 19503103
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibition of cleavage of the third component of human complement (C3) by its small cleavage fragment, C3a: inhibition occurs with the classical-pathway, but not the alternative-pathway, C3 convertase.
    Strunk RC; Webster RO
    Mol Immunol; 1985 Jan; 22(1):37-43. PubMed ID: 3871899
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Solution Structures of Complement C2 and Its C4 Complexes Propose Pathway-specific Mechanisms for Control and Activation of the Complement Proconvertases.
    Mortensen S; Jensen JK; Andersen GR
    J Biol Chem; 2016 Aug; 291(32):16494-507. PubMed ID: 27252379
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The role of properdin in the assembly of the alternative pathway C3 convertases of complement.
    Hourcade DE
    J Biol Chem; 2006 Jan; 281(4):2128-32. PubMed ID: 16301317
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evidence for the involvement of arginine 462 and the flanking sequence of human C4 beta-chain in mediating C5 binding to the C4b subcomponent of the classical complement pathway C5 convertase.
    Ebanks RO; Isenman DE
    J Immunol; 1995 Mar; 154(6):2808-20. PubMed ID: 7876551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.